Illustration: Lazaro Gamio / Axios
Biotech Amicus Therapeutics will license a rare kidney disease treatment for $560 million, in the third such deal this week.
Why it matters: Pharma and biotech is ramping interest in rare disease treatments, where much of R&D is currently concentrated.
